Synchron Secures US$200 Million in Series D Financing
Synchron has successfully raised US$200 million in a Series D funding round. This capital will accelerate the commercialization of its first-generation Stentrode brain-computer interface (BCI) platform and support the development of a next-generation, transcatheter, high-channel whole-brain interface.
Advancing Brain-Computer Interface Technology
The company plans to use the funding to speed up pivotal trials and prepare for the commercial launch of the Stentrode BCI system. Alongside this, Synchron intends to expand its team by hiring engineers, neuroscientists, and operators to advance future BCI innovations.
Investment Round Details
The Series D round was led by Double Point Ventures, joined by existing investors such as ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors include the Australian National Reconstruction Fund (NRF), T Rx Capital, Qatar Investment Authority (QIA), K5 Global, Protocol Labs, and IQT.
Funding Impact
This financing round increases Synchron’s total funding to US$345 million, according to the company's latest announcement.
"Bolstered by this Series D funding, Synchron will continue hiring engineers, neuroscientists and operators to advance the next generation of BCIs."
Synchron's significant funding boost will fast-track cutting-edge brain interface technology from trials to market, reinforcing its leadership in the BCI field.